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Objectives: To determine the value of &natured homologous vein grafts as a conduit for secondary haemodialysis 
access. 
Design: Retrospective clinical study. 
Setting: 2 University Hospitals. 
Materials and Methods: One-hundred-and-twenty-five patients received 195 grafts over a period of five years. Fifty-six 
first grafts (45%)functioned without complications throughout the study period of 5.8 years. 
Main Results: Primary patency was 57% after I year and 25% after 3 years of foUow-up. Of the initial grafts, 69 (55%) 
needed 161 interventions, for thrombosis (n = 59), stenosis (n = 43), failure beyond repair (n = 40), aneurysm (n = 12), 
infection (n = 4), steal syndrome (n = 1), and other causes (n = 2). Secondary patency was 76% at 1 year and 52% at 
3 years of follow-up. A major advantage ofthese grafts was the low rate (2.6%) of infection. Aneurysmformation occurred 
17 times in 195 grafts (8.7%). 
Conclusions: Denatured homologous vein graft is a good alternative in secondary access urgery. 
Key Words: Haemodialysis; Vascular access; Secondary vascular access; Homologous vein; Varivas; Secondary access 
surgery. 
Introduction 
Since the development of the artificial kidney by Kolff 
in 1943, chronic intermittent haemodialysis has been 
applied to patients with failing kidneys. In January 
1988, a total of 2198 haemodialysis patients were 
registered in the Netherlands. By January 1993 this 
number of patients had increased to 2514.1 The 
feasibility and quality of successful haemodialysis 
depends entirely upon adequate access to the circu- 
latory system. Currently the most common method of 
vascular access is the Brescia/Cimino fistula which 
was described in 1966. 2 In 20-30% of the patients, 
however, this radio-cephalic fistula gives insufficient 
access to the circulation, due to inadequate vein or 
artery size, or deficient maturation of the fistula. 3"4 
Thrombosis due to stenosis in the proximal vein at or 
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just above the anastomosis accounts for most late 
failures. This results in a 1-year cumulative patency 
rate of 80-85% and a 3-year cumulative patency rate of 
70_80%.5, 6Whenever a Brescia/Cimino fistula fails or 
cannot be constructed an alternate way of vascular 
access has to be found. These alternatives involve the 
use of autografts, homografts, emibiological grafts or 
synthetic prostheses in a so-called secondary access 
operation. Because atherosclerosis has a high preva- 
lence in patients with renal failure, the saphenous vein 
is usually reserved for possible peripheral bypass or 
CABG surgery. Masselot, Bonnaud et al. first described 
the use of saphenous allografts for secondary blood 
access in 1977. 7 Since January 1983 a denatured 
homologous vein prosthesis (Varivas-Medicor, Hol- 
land) has become available. It has been used as 
material for arteriovenous shunts, aorto-pulmonary 
shunts, femoro-popliteal bypasses and recently 
femoro-tibial bypasses. 8 This retrospective cohort 
study presents the results of secondary access urgery 
with this graft material. 
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Patients and Methods 
The grafts are harvested from saphenous vein 
stripped during varicose vein surgery. The best sam- 
ples are collected aseptically in vials containing 0.01% 
chlorohexidine solution. After storage at 4°C for at 
least 4 weeks in this chlorohexidine solution which 
destroys antigenicit~ the preparation procedure is 
undertaken. Quality selection criteria are: 1) regularity 
and length of the vein segment; 2) the size of the inner 
vessel diameter from 5 to 8 ram; and 3) the macro- 
scopic appearance of the vascular wall. Collaterals are 
ligated using 5 × 0 prolene and to acquire a useful 
length of the prosthesis, shorter segments are anasto- 
mosed with 6 × 0 prolene. A leakage test is performed 
using isotonic saline solution under 200 mmHg 
pressure. 9 Finally the prosthesis, maintained in posi- 
tion by a glass rod through the lumen is inserted in a 
stoppered glass cylinder containing 0.02 g chlor- 
amphenicol per 100 ml isotonic saline solution. In a 
secondary access operation the prosthesis is anasto- 
mosed end-to-side to the brachial artery just distal to 
the flexion crease at the elbow. The remaining length 
of the homograft is placed subcutaneously in a loop at 
the forearm through one or two stab incisions. The 
terminal portion of the loop is anastomosed end-to- 
side to a suitable vein in the cubital fossa, usually the 
cephalic or cubital vein. 1° In all cases antibiotic 
prophylaxis with 1000 mg flucloxacillin during the 
operation followed by 500 mg four times a day for 2 
days was employed. After implantation a period of at 
least 2 weeks was allowed for healing of the subcuta- 
neous tissue before using the shunt for 
haemodialysis. 
Between January 1988 and October 1993 all 125 
patients with renal insufficiency that needed secon- 
dary access urgery for haemodialysis were included 
in this study. Only patients in whom a Cimino/Brescia 
fistula could not be accomplished in a satisfactory 
wa~ because the veins or arteries were not suitable 
(25%) or because the primary operation had failed 
(75%) entered this study. Patients that had previously 
undergone secondary access surgery before January 
1988 were excluded. The details of all interventions 
necessary to keep the arteriovenous graft functioning 
well  were registered. The study focussed on the 
occurrence of complications and interventions. The 
following findings were regarded as graft failures: 
thrombosis; stenosis requiring intervention; infection; 
aneurysm; and steal syndrome. Even if the shunt was 
still functional with an aneurysm or infection, but 
surgical intervention was necessary, the graft was 
considered to have failed. 
The primary patency rate was defined as the 
percentage of shunts that functioned well without 
surgical intervention at different intervals after 
implantation of the prosthesis. The secondary patency 
rate was defined as the percentage of patent shunts, 
including those requiring surgical intervention for 
graft failure. To calculate the primary and secondary 
patency the Kaplan-Meier method was used. 11 
Patients that stopped haemodialysis during CAPD 
treatment or after kidney transplantation with a 
functional shunt were deemed dropouts as were 
patients who died with a patent shunt. In all other 
cases the end point was failure beyond repair of the 
secondary access hunt. The Cox proportional hazards 
survival analysis was used to assess the effect of risk 
factors on patency rates. 
Results 
There were 57 males and 68 females and the mean age 
at the first operation was 54.3 years (range: 19-79 
years). Eighteen patients had a documented history of 
atherosclerotic vascular disease, 15 patients had dia- 
betes mellitus and 17 a combination of both. Table 1 
Table 1. Number of graft shunts and interventions 
Number of patients Number of patients Total of 
with one or more interventions* 
interventions* 
First graft 125 69 (55%) 161 
Second graft 40 24 (60%) 53 
Third graft 16 14 (88%) 16 
Fourth graft 7 5 (71%) 8 
Fifth graft 4 4 (100%) 5 
Sixth graft 3 2 (67%) 3 
Total 195 118 246 
* These interventions include implantations of new secondary 
access shunts after failure beyond repair of a previous one. 
gives an overview of the number of interventions 
required to maintain shunt patency and the number of 
homologous vein prostheses used in each patient. A 
total of 195 shunts were implanted during the study 
period and a total of 246 interventions performed. 
During this study 34 patients (27.2%) died (mean age 
60.0, range: 19.1-81.4 years), 13 (10.4%) underwent a
successful kidney transplantation, four (3.2%) 
changed to CAPD and seven (5.6%) changed to 
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another type of A-V shunt (e.g. an Al len-Brown or 
Scribner shunt). 
In 56 (44.8%) secondary arter iovenous shunts the 
graft funct ioned wi thout  complications throughout  
the study or until t ime of death or end of haemodial -  
ysis. The mean fol low-up of these shunts was 367 days 
(range: 1-1911). A total of 13 (10.4%) shunts failed 
beyond repair and were replaced by  a second graft. 
Consequent ly  12 patients received a homologous  vein 
prosthesis and one an Al len-Brown shunt. The mean 
period between the first operat ion and the replace- 
ment  by  these second grafts was 308 days (range: 
13-1673 days). In 56 (44.8%) shunts at least one 
intervention, other than implantat ion of a new shunt, 
was per formed to keep the graft patent. The mean 
period between the first operat ion and the first 
intervention was 250 days (range: 0-1155 days). In 29 
of the latter 56 patients the graft failed beyond repair 
after one or more interventions and a second graft was 
Tab le  2. Ind icat ions  and  in tervent ions  per fo rmed a f te r  failure of 
the  f i rst  shunt  
Indications for intervention Interventions performed 
Thrombosis 59 Thrombectomy 55 
Stenosis 43 New graft 40 
Failure beyond repair 40 Patch 33 
Aneurysm* 12 Interposition 27 
Infection 4 PTA and other 6 
Steal syndrome 1 Total 161 
Other causes 2 
Total 161 
* A total of 12 aneurysms were found: 11 true aneurysms and i false 
aneurysm 
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Fig. 1. Life table: primary cumulative patency of the first, second and third shunt. 
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Tab le  3. Ind icat ions  and  in tervent ions  per fo rmed a f te r  fa i lu re  of 
a l l  shunts  
Indications for intervention Interventions performed 
Thrombosis 85 Thrombectomy 
Failure beyond repair 70 New graft 
Stenosis 65 Patch 
Aneurysm* 17 Interposition 
Infection 5 PTA 
Steal syndrome 1 Ligation shunt 
Other causes 3 Other 
Total 246 Total 
* A total of 17 aneurysms were found: 12 true aneurysms and 5 false 
aneurysms 
implanted to continue haemodialysis (28 homologous 
vein grafts and one Allen-Brown shunt). 
The indications for intervention and the type of 
76 intervention are detailed in Table 2. The mean patent 
period between the first and the second shunt was 409 
70 days (range: 13-1914 days). Table 3 lists the indica- 
47 tions and interventions performed after failure of all 
the shunts. The primary and secondary cumulative 
39 patency rates are shown in the life table in Figs 1 and 
2. Patients with an atherosclerotic vascular disease or 3 
diabetes mellitus did not have a significantly higher 
4 relative risk of complications with the A-V shunt han 
those without hese diseases. The hazard ratios were 7 
1.26 (p = 0.42) for atherosclerosis and 1.32 (p = 0.30) 
246 for diabetes mellitus. In patients aged 55 years or more 
the relative risk for occlusion of the shunt was 
significantly higher than in patients below this age. 
The hazard ratio was 2.1 (p = 0.03) with a 95% 
confidence interval of 1.1-3.9. 
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Fig. 2. Life table: secondary cumulative patency of the first, second and third shunt. 
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Discussion 
Whenever a Brescia/Cimino fistula fails, or cannot be 
constructed an alternative has to be offered to the 
patient. This alternative is usually an arteriovenous 
graft shunt. In the last decade several kinds of graft 
materials have been used. May et al, were the first to 
report the use of saphenous vein. 12 The published 
cumulative patency rates of this material vary from 
20-80% at 1 year and 20-60% at 3 years of follow- 
up. 13'14'15 Today polytetrafluoroethylene (PTFE) is 
the most popular graft material for secondary access 
surgery. It was first introduced by Baker in 197616 and 
the published cumulative patency rates range from 
60-87% at 1 year and 45-69% at 3 years. 3" 17,18 Major 
complications of PTFE grafts are infection (10-25%) 
and the occurrence of false aneurysms (6--8%). 17' 18,19 
In our hospital we prefer to use denatured 
homologous vein as conduit for secondary access 
surgery. In this study the secondary patency of the 
first homologous vein shunt was 75.7% at 1 year and 
52.4% at 3 years. To obtain this patency 55.2% of the 
patients had to undergo at least one intervention. The 
most: common causes of failure were thrombosis or 
stenosis (63,4%). Thrombosis was frequently seen after 
hypotensive periods (e.g. due to general anaesthesia 
or cardiac failure), kidney transplantation and possi- 
bly the administration oferythropoetin. 2° Stenosis due 
to intimal hyperplasia t the venous anastomogis of 
the shunt was usually the cause of thrombosis. 
Aneurysm formation and infection are major 
complications that could threaten the shunt, the limb 
or even the life of a patient. 17' 18~ 19, 21 In this series the 
infection rate was low (2.6%: five infections in 195 
shunts) and was treated in all cases by interposition of 
a short homologous vein segment thus bypassing the 
infected area that was incised and drained with no 
complications. Infection occurred after puncture of the 
shunt and the infection was always localised to the 
puncture site with no tunnel infections een. Aneu- 
rysms were always treated before bleeding occurred. 
The aneurysms were removed by excision in toto and 
primary anastomosis of the remaining ends, or by 
interposition of a short homologous vein segment 
with no complications. 
Diabetes and atherosclerotic Vascular disease are 
general risk factors to the vascular system 22 however 
no significant correlation was found between them 
and the pattern of vascular access (e.g. more secon- 
dary access). Burger et al. reported a 7% rate of 
diabetes mellitus, whereas Tordoir et al. found 15.1% 
diabetes and 8.1% atherosclerotic disease in haemo- 
dialysis patients. 18' 23 In our study 28% of the patients 
had atherosclerotic vascular disease and 25.6% dia- 
betes mellitus. Despite this high percentage ofpatients 
in a poor physical condition and the fact that we 
registered all surgical interventions as graft failures, 
our results are comparable to the results concerning 
PTFE grafts. Homologous vein handles wel l  much 
like autologous saphenous vein compared to the more 
rigid PTFE prosthesis. Another major advantage of 
this graft is the low rate and limited extent of 
infection. The occurrence of aneurysm formation in 
denatured homologous vein is comparable to the 
published results for the PTFE prosthesis. 17" 18,19 A 
disadvantage is the fact that denatured homologous 
vein prostheses are costly (about hree times the price 
of PTFE). 
In order to determine whether denatured homol- 
ogous vein is better than PTFE we recently have 
started a randomised multicentre prospective study. 
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